The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

AstraZeneca PLC

NYSE: AZN
Last

(U.S.) $28.26

Today's change-0.66 -2.28%
Updated May 4 4:03 PM EDT. Delayed by at least 15 minutes.
 

AstraZeneca PLC

NYSE: AZN
Last

(U.S.) $28.26

Today's change-0.66 -2.28%
Updated May 4 4:03 PM EDT. Delayed by at least 15 minutes.

AstraZeneca PLC down (U.S.)$0.66

AstraZeneca PLC closed sharply lower Wednesday, dropping (U.S.)$0.66 or 2.28% to (U.S.)$28.26. Over the last five days, shares have lost 3.94% and sit 2.10% above their 52-week low. This security has underperformed the S&P 500 by 14.50% during the last year.

Key company metrics

  • Open(U.S.) $28.20
  • Previous close(U.S.) $28.92
  • High(U.S.) $28.35
  • Low(U.S.) $28.08
  • Bid / Ask(U.S.) $28.27 / (U.S.) $28.34
  • YTD % change-16.76%
  • Volume4,891,973
  • Average volume (10-day)3,750,418
  • Average volume (1-month)3,769,066
  • Average volume (3-month)4,473,283
  • 52-week range(U.S.) $27.68 to (U.S.) $35.34
  • Beta0.71
  • Trailing P/E24.48×
  • P/E 1 year forward14.43×
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend(U.S.) $1.40
  • Dividend yield4.95%
  • Trailing EPS(U.S.) $1.15
Updated May 4 4:03 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+11.71%

Based on its net profit margin of 11.71%, AstraZeneca PLC is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.55%Sector:Industry:
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2015Q3/2015Q2/2015Q1/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015
Revenue6,3995,9456,3076,057
Total other revenue--------
Total revenue6,3995,9456,3076,057
Gross profit5,1644,9275,2984,831
Total cost of revenue1,2351,0181,0091,226
Total operating expense5,3114,7755,3845,124
Selling / general / administrative2,5602,2992,3002,445
Research & development1,5671,4001,3561,280
Depreciation / amortization360234376265
Interest expense (income), net operating--------
Unusual expense (income)102322343321
Other operating expenses, total-513-4980-413
Operating income1,0881,170923933
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax802931658678
Income after tax808770696552
Income tax, total-6161-38126
Net income808770697550
Total adjustments to net income--------
Net income before extra. items808770697550
Minority interest001-2
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items808770697550
Inc. avail. to common incl. extra. items808770697550
Diluted net income808770697550
Dilution adjustment00--0
Diluted weighted average shares1,2651,2651,2651,265
Diluted EPS excluding extraordinary itemsvalue per share0.640.610.550.43
Dividends per sharevalue per share1.900.000.900.00
Diluted normalized EPSvalue per share0.860.860.830.70